3 days ago
5
Oslo, Norway, 26 March, 2025
Reference is made to the stock exchange notice published by Zelluna ASA (the "Company") published on 26 March 2025 regarding the resolution by the Company's board of directors to carry out a share capital increase of NOK 0.70 through the issuance of seven (7) new shares in the Company in order to achieve a desirable ratio for the reverse share split.
The Company has received the following notification of a transaction made by a close associate of a primary insider:
- Radforsk Investeringsstiftelse, a close associate of chair of the board of directors and primary insider of the Company, Anders Tuv, has today subscribed for seven (7) new shares in the Company at a subscription price of NOK 2.60 (equal to the price per share in the recently completed business combination and private placement). Following this transaction, Radforsk Investeringsstiftelse hold 24,714,221 shares in Zelluna ASA.
Get the latest news
delivered to your inboxSign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.
The notification concerning the above subscription is attached hereto.
For further information, please contact:
Hans Vassgård Eid, CFO, Zelluna ASA
Email: [email protected]
Phone: +47 482 48632
About Zelluna ASA
Zelluna's mission is to deliver transformative treatments with the capacity to cure advanced solid cancers, in a safe and cost-efficient manner, to patients on a global scale. The Company aims to do this by combining the most powerful elements of the immune system through pioneering the development of "off the shelf” T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). The TCR-NK platform offers a unique mechanism of action with broad cancer detection capability to overcome the diversity of tumours and will be used "off the shelf” to overcome scaling limitations of current cell therapies. The lead program is a world's first MAGE-A4 targeting "off the shelf” TCR-NK for the treatment of various solid cancers; a pipeline of earlier products follows. The Company is led by a management team of biotech entrepreneurs with deep experience in discovery through to clinical development of TCR and cell-based therapies including marketed products.
Attachment
